Vixarelimab

• CAT Number: I042135
• CAS Number: 2243320-83-2
• Purity: ≥95%

Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash[1].
Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) results in increased MCP-1/CCL2 levels at a concentration of 0.0001 μg/mL in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF) cells and a significant decrease in MCP-1/CCL2 levels in both cells at concentrations of 0.001 μg/mL or higher[1].
Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) pretreatment results in reduced levels of MCP-1/CCL2 in both Oncostatin M (OSM) induced as well as OSM plus IL-4 induced HEK and HDF cells and the maximum effect is observed at concentrations of 0.01 μg/mL and 0.1 μg/mL[1].

Reference

[1]. Carl D Richards, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020 Jul 2;100(14):adv00197.
 [Content Brief]